Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Sold by HealthInvest Partners AB

HealthInvest Partners AB lessened its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 20.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 120,501 shares of the company’s stock after selling 31,374 shares during the period. Harmony Biosciences accounts for about 1.9% of HealthInvest Partners AB’s holdings, making the stock its 18th biggest position. HealthInvest Partners AB owned approximately 0.21% of Harmony Biosciences worth $4,104,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CWM LLC increased its holdings in shares of Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after purchasing an additional 775 shares during the period. Creative Planning acquired a new position in Harmony Biosciences in the 3rd quarter valued at $246,000. Mirae Asset Global Investments Co. Ltd. raised its position in Harmony Biosciences by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock worth $80,000 after buying an additional 360 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Harmony Biosciences by 8,867.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,560 shares of the company’s stock worth $222,000 after acquiring an additional 5,498 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Harmony Biosciences by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,931 shares of the company’s stock valued at $437,000 after acquiring an additional 4,259 shares in the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on HRMY. Oppenheimer reissued an “outperform” rating and set a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of Harmony Biosciences in a research note on Wednesday, February 19th. Deutsche Bank Aktiengesellschaft assumed coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price target on the stock. Mizuho cut their price objective on Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, Cantor Fitzgerald boosted their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Harmony Biosciences currently has a consensus rating of “Buy” and an average price target of $53.67.

Insider Buying and Selling at Harmony Biosciences

In related news, CEO Jeffrey M. Dayno sold 19,293 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total transaction of $774,228.09. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Sandip Kapadia sold 25,000 shares of Harmony Biosciences stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00. The disclosure for this sale can be found here. In the last three months, insiders sold 72,452 shares of company stock worth $2,831,679. 30.80% of the stock is owned by corporate insiders.

Harmony Biosciences Trading Down 0.9 %

NASDAQ:HRMY opened at $34.56 on Monday. Harmony Biosciences Holdings, Inc. has a 52-week low of $28.14 and a 52-week high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The stock has a fifty day simple moving average of $36.57 and a 200-day simple moving average of $35.81. The company has a market capitalization of $1.97 billion, a PE ratio of 16.38, a price-to-earnings-growth ratio of 0.47 and a beta of 0.80.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.